AIM ImmunoTech Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>AIM ImmunoTech Inc. has filed its quarterly report (10-Q) for the period ending March 31, 2024, detailing its financial and operational status.</b>

AI Summary

AIM ImmunoTech Inc. (AIM) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. AIM ImmunoTech Inc. filed a 10-Q report for the quarter ended March 31, 2024. The filing covers the period from January 1, 2024, to March 31, 2024. The company's principal business address is 2117 SW Highway 484, Ocala, FL 32801. AIM ImmunoTech Inc. was formerly known as Hemispherx Biopharma Inc., with a name change on June 14, 1995. The SIC code for the company is 2836, Biological Products (No Diagnostic Substances).

Why It Matters

For investors and stakeholders tracking AIM ImmunoTech Inc., this filing contains several important signals. This 10-Q filing provides investors and stakeholders with the latest financial performance and operational updates for AIM ImmunoTech Inc. during the first quarter of 2024. Understanding the details within this report is crucial for assessing the company's current financial health, strategic direction, and potential future performance in the biopharmaceutical sector.

Risk Assessment

Risk Level: — AIM ImmunoTech Inc. shows moderate risk based on this filing. The filing is a standard 10-Q, which is a routine quarterly report and does not contain significant new risks or material adverse events beyond typical business operations.

Analyst Insight

Review the detailed financial statements and management's discussion and analysis within the 10-Q to understand AIM ImmunoTech's performance and outlook for Q1 2024.

Key Numbers

• 2024-03-31 — Reporting Period End Date (10-Q filing)
• 2024-01-01 — Reporting Period Start Date (10-Q filing)
• 1995-06-14 — Date of Name Change (From Hemispherx Biopharma Inc.)

Key Players & Entities

• AIM ImmunoTech Inc. (company) — Filer
• Hemispherx Biopharma Inc. (company) — Former company name
• 2117 SW Highway 484, Ocala, FL 32801 (location) — Business and mailing address
• 2836 (industry_code) — Standard Industrial Classification

FAQ

Industry Context

AIM ImmunoTech Inc. operates in the biotechnology and pharmaceutical industry, focusing on the development of therapeutics for cancer and immune-related diseases.

Regulatory Implications

The company is subject to standard SEC regulations for public companies, including the requirement to file quarterly reports (10-Q) detailing financial performance and business operations.

What Investors Should Do

1. Analyze the financial statements for revenue, expenses, and cash flow for Q1 2024.
2. Review any disclosures regarding clinical trials, regulatory approvals, or product development pipelines.
3. Assess the company's liquidity and capital structure based on the balance sheet information.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
• 2024-05-15: Filing Date — Date the 10-Q was filed with the SEC.

Year-Over-Year Comparison

This is the initial filing analyzed for the current period. Previous filings would need to be compared for year-over-year or sequential changes.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Indic
• $250,000 — ement allows the Lender to redeem up to $250,000 per calendar month beginning in August

Filing Documents

• form10-q.htm (10-Q) — 935KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 18KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-24-019917.txt (&nbsp;) — 5543KB
• aim-20240331.xsd (EX-101.SCH) — 47KB
• aim-20240331_cal.xml (EX-101.CAL) — 62KB
• aim-20240331_def.xml (EX-101.DEF) — 217KB
• aim-20240331_lab.xml (EX-101.LAB) — 380KB
• aim-20240331_pre.xml (EX-101.PRE) — 305KB
• form10-q_htm.xml (XML) — 754KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 52-0845822 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 2117 SW Highway 484 , Ocala FL 34473 (Address of principal executive offices) (Zip Code) (352) 448-7797 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.001 per share AIM NYSE American Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No 51,281,437 shares of common stock were outstanding, and no shares of series B preferred stock were outstanding as of May 13, 2024. PART I- FINANCIAL INFORMATION ITEM 1 : Financial Statements AIM IMMUNOTECH INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (in thousands, except for share and per share amounts) (Unaudited March 31, 2024 and Audited December 31, 2023) March 31, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 3,295 $ 5,439 Marketable investments 7,647 7,631 Funds receivable from New Jersey net operating loss and Other Receivables — 1,184 Prepaid expenses and other current assets 364 302 Total current assets 11,306 14,556 Property and equipment, net 118 127 Right of use asset, net 763 697 Patent and trademark rights, net 2,314 2,313 Other assets 1,688 1,688 Total assets $ 16,189 $ 19,381 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 6,567 $ 6,443 Accrued expenses 1,446 1,986 Current portion of operating lease liability 240 223 Current portion of note payable, net 1,623 — Total current liabilities 9,876 8,652 Long-term liabilities: Operating lease liability 537 495 Note payable, net 950 — Total liabilities 11,363 9,147 Commitments and contingencies (Notes 9, 10 and 14) - Stockholders' equity: Series A Junior Participating Preferred Stock, $ 0.001 par value, 4,000,000 and 250,000 shares authorized as of March 31, 2024, and December 31, 2023, respectively; issued and outstanding – none — — Series B Convertible Preferred Stock, stated value $ 1,000 per share, 10,000 shares authorized; 689 and 689 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 689 689 Preferred Stock, Value Common Stock, $ 0.001 par value, authorized shares - 350,000,000 ; issued and outstanding shares 50,251,933 and 49,102,484 as of March 31, 2024 and December 31, 2023, respectively 50 49 Additional paid-in capital 419,412 419,004 Accumulated deficit ( 415,325 ) ( 409,508 ) Total stockholders' equity 4,826 10,234 Total liabilities and stockholders' equity $ 16,189 $ 19,381 See accompanying notes to consolidated financial statements. 2 AIM IMMUNOTECH INC. AND SUBSIDIARIES Consolidated (in thousands, except share and per share data) (Unaudited) 2024 2023 Three months ended March 31, 2024 2023 Revenues: Clinical treatment programs – US $ 40 $ 49 Total Revenues 40 49 Costs and E

View Full Filing

View this 10-Q filing on SEC EDGAR